Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. more
Time Frame | ACIU | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.18% | -1.66% | 0.16% |
1-Month Return | -0.95% | -3.08% | 1% |
3-Month Return | 2.95% | -6.66% | 10.69% |
6-Month Return | -30.38% | -1.54% | 12.9% |
1-Year Return | -18.65% | 8.85% | 30.94% |
3-Year Return | -38.91% | 7.9% | 29.66% |
5-Year Return | -63.78% | 45.12% | 92.82% |
10-Year Return | -79.95% | 104.55% | 193.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 111.03M | 15.43M | 944.00K | 3.94M | 14.80M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":13.9,"profit":true},{"date":"2021-12-31","value":0.85,"profit":true},{"date":"2022-12-31","value":3.54,"profit":true},{"date":"2023-12-31","value":13.33,"profit":true}] |
Cost of Revenue | 50.43M | 59.49M | 62.28M | 60.34M | 54.61M | [{"date":"2019-12-31","value":80.97,"profit":true},{"date":"2020-12-31","value":95.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.88,"profit":true},{"date":"2023-12-31","value":87.68,"profit":true}] |
Gross Profit | 60.59M | (44.06M) | (62.28M) | (56.40M) | (39.80M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-72.71,"profit":false},{"date":"2021-12-31","value":-102.79,"profit":false},{"date":"2022-12-31","value":-93.08,"profit":false},{"date":"2023-12-31","value":-65.69,"profit":false}] |
Gross Margin | 54.58% | (285.50%) | (6597.67%) | (1433.32%) | (268.93%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-523.13,"profit":false},{"date":"2021-12-31","value":-12088.87,"profit":false},{"date":"2022-12-31","value":-2626.26,"profit":false},{"date":"2023-12-31","value":-492.77,"profit":false}] |
Operating Expenses | 66.49M | 76.69M | 79.01M | 74.78M | 13.82M | [{"date":"2019-12-31","value":84.15,"profit":true},{"date":"2020-12-31","value":97.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.65,"profit":true},{"date":"2023-12-31","value":17.49,"profit":true}] |
Operating Income | 44.54M | (61.26M) | (79.01M) | (70.85M) | (53.62M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-137.55,"profit":false},{"date":"2021-12-31","value":-177.41,"profit":false},{"date":"2022-12-31","value":-159.08,"profit":false},{"date":"2023-12-31","value":-120.41,"profit":false}] |
Total Non-Operating Income/Expense | (717.00K) | (767.00K) | 11.92M | (179.00K) | 269.00K | [{"date":"2019-12-31","value":-6.01,"profit":false},{"date":"2020-12-31","value":-6.43,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1.5,"profit":false},{"date":"2023-12-31","value":2.26,"profit":true}] |
Pre-Tax Income | 45.44M | (61.92M) | (72.99M) | (70.74M) | (54.22M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-136.26,"profit":false},{"date":"2021-12-31","value":-160.63,"profit":false},{"date":"2022-12-31","value":-155.67,"profit":false},{"date":"2023-12-31","value":-119.32,"profit":false}] |
Income Taxes | 1.89M | 184.00K | 3.00K | 13.00K | 10.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":9.71,"profit":true},{"date":"2021-12-31","value":0.16,"profit":true},{"date":"2022-12-31","value":0.69,"profit":true},{"date":"2023-12-31","value":0.53,"profit":true}] |
Income After Taxes | 43.55M | (62.10M) | (73.00M) | (70.75M) | (54.23M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-142.61,"profit":false},{"date":"2021-12-31","value":-167.62,"profit":false},{"date":"2022-12-31","value":-162.47,"profit":false},{"date":"2023-12-31","value":-124.54,"profit":false}] |
Income From Continuous Operations | 45.44M | (61.92M) | (73.00M) | (70.75M) | (54.23M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-136.26,"profit":false},{"date":"2021-12-31","value":-160.64,"profit":false},{"date":"2022-12-31","value":-155.7,"profit":false},{"date":"2023-12-31","value":-119.35,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 45.44M | (62.10M) | (73.00M) | (70.75M) | (54.23M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-136.67,"profit":false},{"date":"2021-12-31","value":-160.64,"profit":false},{"date":"2022-12-31","value":-155.7,"profit":false},{"date":"2023-12-31","value":-119.35,"profit":false}] |
EPS (Diluted) | 0.69 | (0.84) | (0.99) | (0.85) | (0.64) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-121.74,"profit":false},{"date":"2021-12-31","value":-143.48,"profit":false},{"date":"2022-12-31","value":-123.19,"profit":false},{"date":"2023-12-31","value":-92.75,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ACIU | |
---|---|
Cash Ratio | 1.56 |
Current Ratio | 1.86 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ACIU | |
---|---|
ROA (LTM) | -12.04% |
ROE (LTM) | -31.16% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ACIU | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.47 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.53 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ACIU | |
---|---|
Trailing PE | NM |
Forward PE | 7.68 |
P/S (TTM) | 7.61 |
P/B | 2.10 |
Price/FCF | NM |
EV/R | 2.90 |
EV/Ebitda | NM |
PEG | NM |
AC Immune Ltd (ACIU) share price today is $3.125
Yes, Indians can buy shares of AC Immune Ltd (ACIU) on Vested. To buy AC Immune Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACIU stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of AC Immune Ltd (ACIU) via the Vested app. You can start investing in AC Immune Ltd (ACIU) with a minimum investment of $1.
You can invest in shares of AC Immune Ltd (ACIU) via Vested in three simple steps:
The 52-week high price of AC Immune Ltd (ACIU) is $5.14. The 52-week low price of AC Immune Ltd (ACIU) is $2.25.
The price-to-earnings (P/E) ratio of AC Immune Ltd (ACIU) is
The price-to-book (P/B) ratio of AC Immune Ltd (ACIU) is 2.10
The dividend yield of AC Immune Ltd (ACIU) is 0.00%
The market capitalization of AC Immune Ltd (ACIU) is $311.67M
The stock symbol (or ticker) of AC Immune Ltd is ACIU